Literature DB >> 10359567

Apo E structure determines VLDL clearance and atherosclerosis risk in mice.

C Knouff1, M E Hinsdale, H Mezdour, M K Altenburg, M Watanabe, S H Quarfordt, P M Sullivan, N Maeda.   

Abstract

We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo E protein and have compared them with mice expressing the human apo E3 isoform. Plasma lipid and apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL competed with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together with our earlier observations in wild-type and human APOE*2-replacement mice, demonstrate a direct and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size. Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL residence time and atherosclerosis risk in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359567      PMCID: PMC408371          DOI: 10.1172/JCI6172

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 2.  Lipoproteins and atherosclerosis. A look back and a look ahead.

Authors:  D Steinberg
Journal:  Arteriosclerosis       Date:  1983 Jul-Aug

3.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

4.  Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages.

Authors:  P Cullen; A Cignarella; B Brennhausen; S Mohr; G Assmann; A von Eckardstein
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor.

Authors:  M F Linton; A H Hasty; V R Babaev; S Fazio
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

6.  Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.

Authors:  K H Weisgraber; S C Rall; R W Mahley; R W Milne; Y L Marcel; J T Sparrow
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

7.  Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

Authors:  M M Véniant; C H Zlot; R L Walzem; V Pierotti; R Driscoll; D Dichek; J Herz; S G Young
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

8.  NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.

Authors:  H B Brewer; L A Zech; R E Gregg; D Schwartz; E J Schaefer
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

9.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.

Authors:  P M Sullivan; H Mezdour; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.

Authors:  J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1974-08-25       Impact factor: 5.157

View more
  129 in total

1.  Presence of oestrogen receptor type beta in human retina.

Authors:  C Munaut; V Lambert; A Noël; F Frankenne; M Deprez; J M Foidart; J M Rakic
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Isoform-dependent effects of apoE on doublecortin-positive cells and microtubule-associated protein 2 immunoreactivity following (137)Cs irradiation.

Authors:  Laura Villasana; Timothy Pfankuch; Jacob Raber
Journal:  Radiat Environ Biophys       Date:  2010-05-11       Impact factor: 1.925

Review 3.  Genetics of lipid traits and relationship to coronary artery disease.

Authors:  Tanya E Keenan; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

4.  Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4.

Authors:  Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  FASEB J       Date:  2010-05-25       Impact factor: 5.191

5.  Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice.

Authors:  Jessica A Siegel; Michael J Craytor; Jacob Raber
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

6.  ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain.

Authors:  Veera Venkata Ratnam Bandaru; Juan Troncoso; David Wheeler; Olga Pletnikova; Jessica Wang; Kathy Conant; Norman J Haughey
Journal:  Neurobiol Aging       Date:  2007-09-20       Impact factor: 4.673

7.  Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds.

Authors:  Nobuyo Maeda; Lance Johnson; Shinja Kim; John Hagaman; Morton Friedman; Robert Reddick
Journal:  Atherosclerosis       Date:  2007-02-01       Impact factor: 5.162

8.  Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease.

Authors:  Yuji Kajiwara; Sonia Franciosi; Nagahide Takahashi; Lisa Krug; James Schmeidler; Kevin Taddei; Vahram Haroutunian; Ulrik Fried; Michelle Ehrlich; Ralph N Martins; Samuel Gandy; Joseph D Buxbaum
Journal:  Mol Neurodegener       Date:  2010-01-14       Impact factor: 14.195

9.  Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.

Authors:  B Teter; T Morihara; G P Lim; T Chu; M R Jones; X Zuo; R M Paul; S A Frautschy; G M Cole
Journal:  Neurobiol Dis       Date:  2019-04-02       Impact factor: 5.996

10.  Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration.

Authors:  G Malek; L V Johnson; B E Mace; P Saloupis; D E Schmechel; D W Rickman; C A Toth; P M Sullivan; C Bowes Rickman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.